- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Haemoglobin analyzers (also known as HbA1c Analyzers) may measure the concentration of haemoglobin in a blood or urine sample in g/L, g/dL, or mol/L. HbA1c Analyzers can perform testing on samples as tiny as 1uL in only a few minutes.As their blood glucose levels rise, more of their haemoglobin will be coated with glucose.
An A1C test determines the percentage of red blood cells that have glucose-coated haemoglobin.The haemoglobin A1c (glycated haemoglobin, glycosylated haemoglobin, HbA1c, or A1c) test is used to assess a person's glucose management.
The test provides a percentage of the average blood sugar level for the previous 90 days. The test can also be used to diagnose diabetes.
The Global HbA1c Analyzer market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Abbott Presents The First-Ever Rapid Point-Of-Care Hba1c Test To Assist In Diabetes Diagnosis.Afinion HbA1c Dx test results are available in three minutes, allowing doctors to construct educated, individualised care plans during patient consultations.
Assay is the first and only fast point-of-care test approved by the FDA to assist healthcare providers in the diagnosis of diabetes. Abbott announced today that the Afinion HbA1c Dx assay is now available for use on both the Afinion 2 Analyzer and the Afinion AS100 Analyzer.
The Afinion HbA1c Dx assay is the first and only quick point-of-care test approved by the US Food and Drug Administration (FDA) to help healthcare providers diagnose diabetes and assess patients' risk of complications.
The Afinion HbA1c Dx satisfies the FDA's strict performance testing standards for diagnostic usage claims. The test provides accurate and precise 1,2 glycated haemoglobin (HbA1c) values in three minutes, allowing physicians to diagnose patients and assist them in developing individualised care plans during a single doctor's office visit.
The Afinion HbA1c Dx assay (licenced for monitoring and diagnosis) supplements the Afinion HbA1c assay (authorised for monitoring alone), the number one point-of-care HbA1c test in the United States for monitoring long-term glycemic control in diabetes.
3 Rapid, dependable diabetes screening at the point of treatment allows healthcare practitioners to promptly connect patients to comprehensive care that can help prevent the disease's devastating effects.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introdauction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in theIndustry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.